The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
Status:
Completed
Trial end date:
2019-04-16
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to assess the PK similarity between patients receiving
Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with
moderate-to-severe chronic plaque psoriasis.
The secondary objectives of this trial are to descriptively compare the safety,
immunogenicity and efficacy profiles between patients receiving Humira® continuously vs those
who alternate between BI 695501 and Humira®.